About Zinc finger protein 57
Zinc finger protein 57 (ZNF57) is a protein
from Homo sapiens identified by UniProt accession
Q68EA5, 555 residues long.
MolForge cross-references it against 0 known binders and
20 disease associations.
Target properties
| Protein name | Zinc finger protein 57 |
| UniProt accession | Q68EA5 |
| Gene | ZNF57 |
| Organism | Homo sapiens |
| Length | 555 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (20)
Diseases linked to this target (Open Targets).
- pancreatic adenocarcinoma · score 0.03
- lung carcinoma · score 0.02
- systemic juvenile idiopathic arthritis · score 0.01
- rosacea · score 0.01
- ulcerative colitis · score 0.01
- neoplasm · score 0.01
- esophageal squamous cell carcinoma · score 0.01
- post-traumatic stress disorder · score 0.00
- cancer · score 0.00
- carcinoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q68EA5-F1 | alphafold | PREDICTED | 68.79 | — |
Amino-acid sequence (555 residues)
MDSVVFEDVA VDFTLEEWAL LDSAQRDLYR DVMLETFRNL ASVDDGTQFK ANGSVSLQDM YGQEKSKEQT IPNFTGNNSC AYTLEKNCEG YGTEDHHKNL RNHMVDRFCT HNEGNQYGEA IHQMPDLTLH KKVSAGEKPY ECTKCRTVFT HLSSLKRHVK SHCGRKAPPG EECKQACICP SHLHSHGRTD TEEKPYKCQA CGQTFQHPRY LSHHVKTHTA EKTYKCEQCR MAFNGFASFT RHVRTHTKDR PYKCQECGRA FIYPSTFQRH MTTHTGEKPY KCQHCGKAFT YPQAFQRHEK THTGEKPYEC KQCGKTFSWS ETLRVHMRIH TGDKLYKCEH CGKAFTSSRS FQGHLRTHTG EKPYECKQCG KAFTWSSTFR EHVRIHTQEQ LYKCEQCGKA FTSSRSFRGH LRTHTGEKPY ECKQCGKTFT WSSTFREHVR IHTQEQLHKC EHCGKAFTSS RAFQGHLRMH TGEKPYECKQ CGKTFTWSST LHNHVRMHTG EKPHKCKQCG MSFKWHSSFR NHLRMHTGQK SHECQSYSKA FSCQVILSKT SESTH
Explore Zinc finger protein 57 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets